Home
NNVC
NNVC News

Latest NanoViricides Inc. (NNVC) News on November 22, 2025

ACCESS Newswire

5 days ago

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

Associated Press Finance

8 days ago

NanoViricides: Fiscal Q1 Earnings Snapshot

ACCESS Newswire

8 days ago

NanoViricides to Present at the Pharma Partnering Summit 2025 in Boston Today, November 14th - NV-387 is Effective Against H3N2

ACCESS Newswire

10 days ago

NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

ACCESS Newswire

11 days ago

NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close

ACCESS Newswire

12 days ago

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo

ACCESS Newswire

17 days ago

NanoViricides Annual Shareholders Meeting to be Held at 10 am on Saturday, November 5th at on Saturday, November 8, 2025, at the Hampton Inn & Suites Stamford, CT

ACCESS Newswire

19 days ago

NanoViricides to Present at the Spartan Capital Investor Conference 2025 in New York City Today, November 3rd

ACCESS Newswire

24 days ago

Treating Measles Infection: Nanoviricides CEO Dr Anil Diwan Interviewed by Steve Darling from Proactive

ACCESS Newswire

a month ago

In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides

ACCESS Newswire

a month ago

A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides - NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus

ACCESS Newswire

a month ago

NanoViricides Dual Track Clinical Strategy Explained by a Research Report - Broad-spectrum Antiviral NV-387 At Phase II Clinical Trial Stage for MPox and also for Acute Respiratory Infections of All Viruses

ACCESS Newswire

2 months ago

NanoViricides, Inc. Has Filed its Annual Report

ACCESS Newswire

5 months ago

With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan

ACCESS Newswire

6 months ago

NanoViricides Measles Drug Development Animal Study is Imminent

ACCESS Newswire

6 months ago

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025

ACCESS Newswire

6 months ago

The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan

ACCESS Newswire

6 months ago

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu

Associated Press Finance

6 months ago

NanoViricides: Fiscal Q3 Earnings Snapshot

ACCESS Newswire

6 months ago

Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution

ACCESS Newswire

6 months ago

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo

Newsfile

7 months ago

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

ACCESS Newswire

7 months ago

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

ACCESS Newswire

7 months ago

Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak

ACCESS Newswire

8 months ago

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

ACCESS Newswire

9 months ago

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire

9 months ago

NanoViricides, Inc. Has Filed its Quarterly Report

Associated Press Finance

9 months ago

NanoViricides: Fiscal Q2 Earnings Snapshot

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?

Insider Monkey

9 months ago

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?

ACCESS Newswire

9 months ago

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

ACCESS Newswire

10 months ago

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

ACCESS Newswire

10 months ago

NanoViricides Engages CRO for Phase II Clinical Trial

ACCESS Newswire

10 months ago

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

ACCESSWIRE

10 months ago

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

ACCESSWIRE

a year ago

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

ACCESSWIRE

a year ago

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

ACCESSWIRE

a year ago

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

Associated Press Finance

a year ago

NanoViricides: Fiscal Q1 Earnings Snapshot

ACCESSWIRE

a year ago

NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am

ACCESSWIRE

a year ago

NanoViricides President Dr. Diwan to Present at the PODD Conference

ACCESSWIRE

a year ago

NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy

Insider Monkey

a year ago

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy

ACCESSWIRE

a year ago

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

ACCESSWIRE

a year ago

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID

ACCESSWIRE

a year ago

NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs

ACCESSWIRE

a year ago

MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX

ACCESSWIRE

a year ago

NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 - A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections

ACCESSWIRE

a year ago

NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

Newsfile

a year ago

Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?

ACCESSWIRE

a year ago

"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides

NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy

Zacks Small Cap Research

a year ago

NNVC: NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift in Viral Therapy

ACCESSWIRE

a year ago

COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides

ACCESSWIRE

a year ago

A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

ACCESSWIRE

a year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

a year ago

A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Is Effective in Protecting Lungs from Damage in Lethally Infected Animal Model

ACCESSWIRE

a year ago

Orally Administered NV-387 Results in Ideal Flat Blood Concentration Profile for Sustained Antiviral Effect

ACCESSWIRE

a year ago

The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

ACCESSWIRE

a year ago

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

ACCESSWIRE

a year ago

NanoViricides Bolsters Partnership Efforts - Engages Aagami Inc.

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

ACCESSWIRE

2 years ago

Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential Cure

Associated Press Finance

2 years ago

NanoViricides: Fiscal Q3 Earnings Snapshot

NanoViricides Has Filed its Quarterly Report

ACCESSWIRE

2 years ago

NanoViricides Has Filed its Quarterly Report

A Novel Broad-Spectrum Antiviral with Activity Against RSV

ACCESSWIRE

2 years ago

A Novel Broad-Spectrum Antiviral with Activity Against RSV

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

ACCESSWIRE

2 years ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

ACCESSWIRE

2 years ago

A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/Mpox

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

ACCESSWIRE

2 years ago

A Novel Broad-Spectrum Antiviral with Activity Against Influenza A

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

ACCESSWIRE

2 years ago

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

ACCESSWIRE

2 years ago

NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

Associated Press Finance

2 years ago

NanoViricides: Fiscal Q2 Earnings Snapshot

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

ACCESSWIRE

2 years ago

Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

ACCESSWIRE

2 years ago

Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events Found

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

ACCESSWIRE

2 years ago

LightPath Technologies Schedules Fiscal 2024 Second Quarter Financial Results Conference Call for February 8, 2024

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

PR Newswire

2 years ago

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

GlobeNewswire

2 years ago

T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients

Duos Secures $2.4 Million AI Subscription and Services Agreement

GlobeNewswire

2 years ago

Duos Secures $2.4 Million AI Subscription and Services Agreement

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

GlobeNewswire

2 years ago

Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Sidoti Events, LLC's Virtual January Micro-Cap Conference

ACCESSWIRE

2 years ago

Sidoti Events, LLC's Virtual January Micro-Cap Conference

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Business Wire

2 years ago

Independent Research Finds 100% Accuracy for Intellicheck Identity Validation Technology

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

GlobeNewswire

2 years ago

Waldencast plc Announces Receipt of Anticipated Nasdaq Delinquency Notice

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Business Wire

2 years ago

Cutera, Inc. Announces Preliminary Unaudited Financial Results for Full-Year 2023

Synlogic Provides Corporate Update and Outlook for 2024

GlobeNewswire

2 years ago

Synlogic Provides Corporate Update and Outlook for 2024

NanoViricides to Present at the Biotech Showcase in San Fransisco

ACCESSWIRE

2 years ago

NanoViricides to Present at the Biotech Showcase in San Fransisco

Comstock (LODE) Executes First Commercial Biorefinery Deal

Zacks

2 years ago

Comstock (LODE) Executes First Commercial Biorefinery Deal

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Business Wire

2 years ago

Velo3D, Inc. Announces $18 Million Registered Direct Offering

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

GlobeNewswire

2 years ago

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Lipocine to Present at Biotech Showcase 2024

PR Newswire

2 years ago

Lipocine to Present at Biotech Showcase 2024

Spectaire Launches AireCore™ Into the Oil and Gas Sector

GlobeNewswire

2 years ago

Spectaire Launches AireCore™ Into the Oil and Gas Sector

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

Business Wire

2 years ago

Velo3D Announces Leadership Transition and Commencement of Strategic Business Review

NextCure Provides Year-End Clinical Pipeline Updates

GlobeNewswire

2 years ago

NextCure Provides Year-End Clinical Pipeline Updates

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Business Wire

2 years ago

Loop Media Reports Full Year 2023 and Fourth Quarter Fiscal Financial Results

Life Science Investor Forum Agenda Announced for December 14th, 2023

GlobeNewswire

2 years ago

Life Science Investor Forum Agenda Announced for December 14th, 2023

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

GlobeNewswire

2 years ago

Spectaire Announces Manufacturing Financing Agreement to Enable Mass Production

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

GlobeNewswire

2 years ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

2 years ago

Aclaris (ACRS) Loses -83.17% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

GlobeNewswire

2 years ago

Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

Insider Monkey

2 years ago

REE Automotive Ltd. (NASDAQ:REE) Q3 2023 Earnings Call Transcript

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

News Direct

2 years ago

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

PR Newswire

2 years ago

MultiMetaVerse Announces Updates of the Taomee Acqusition and Termination of Prior Acquisition Agreement

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

ACCESSWIRE

2 years ago

The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

PR Newswire

2 years ago

BEST Inc. Announces Appointment of Financial Advisor and Legal Counsel to the Special Committee

Share on Social Networks: